Key result
Sacubitril/valsartan significantly reduced NT-proBNP levels at 6 months compared to baseline in Chinese patients with HFrEF (OR 2.587), with higher doses (≥ 200 mg/d) demonstrating greater improvements.
Why the study?
To investigate the dosage pattern, efficacy, and safety of sacubitril/valsartan in Chinese HFrEF patients in real-world settings.
Does sacubitril/valsartan improve NT-proBNP and cardiac function in Chinese patients with HFrEF?
Observational (n=983)
Yes
Does sacubitril/valsartan improve NT-proBNP and cardiac function in Chinese patients with HFrEF?
Odds Ratio: 2.587 (95% CI 1.381–4.848)
p-value: p=0.0031
In a real-world Chinese cohort, sacubitril/valsartan significantly improved NT-proBNP and LVEF in HFrEF patients, with higher doses (>200 mg/d) yielding greater benefits.
Supports sacubitril/valsartan titration in Chinese HFrEF patients; extends ARNI efficacy data to this population.
This study aims to investigate the dosage pattern, efficacy, and safety of sacubitril/valsartan (Sac/Val) in Chinese heart failure with reduced ejection fraction (HFrEF) patients regarding real-world settings. Patients from 27 centers with a confirmed diagnosis of HFrEF and initiated Sac/Val treatment were enrolled. The primary objective was to evaluate the dosage pattern and change of heart failure status. In a final cohort of 983 patients, outpatient Sac/Val treatment demonstrated a similar beneficial effect in NT-proBNP and cardiac function. After initiating the treatment, overall and sub-population showed similar safety and efficacy. Patients who received a higher dose of Sac/Val (> 200 mg/d) demonstrated better improvement in LV function and reduction of NT-proBNP regardless of adjustment. Among Chinese HFrEF patients, Sac/Val showed a comparable reduction in NT-proBNP and improvement in cardiac function. Data further support guideline recommendations of Sac/Val in Chinese population. Optimal up-titration might provide further benefits. Further long-term and prognostic studies are needed.
No takes yet. Share an insight, caveat, or question.
Cheang et al. (2022) conducted an observational in Heart failure with reduced ejection fraction (HFrEF) (n=983). Sacubitril/valsartan vs. Baseline was evaluated on Difference in log-transferred NT-proBNP compared to baseline at 6 months (OR 2.587, 95% CI 1.381-4.848, p=0.0031). Sacubitril/valsartan significantly reduced NT-proBNP levels at 6 months compared to baseline in Chinese patients with HFrEF (OR 2.587), with higher doses (≥ 200 mg/d) demonstrating greater improvements.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: